We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The House Energy & Commerce Committee that oversees the FDA is planning an overhaul of agency procedures to increase orphan drug development, streamline clinical trials oversight, give industry incentives to find new uses for old drugs and expand U.S. drug manufacturing. Read More
President Obama will ask Congress to approve more than $1.2 billion in funding — nearly double the current amount — to fuel development of new antibiotics. Read More
The FDA barred beleaguered drugmaker Ipca Laboratories from shipping drugs to the U.S because of good manufacturing practice violations — the 27th time the agency has cracked down on GMP violations at Indian drug facilities in the last two years. Read More
Actavis will become the UK’s largest generics supplier, once its roughly $461 million acquisition of Auden Mckenzie closes in the first quarter of this year. Read More
The White House released a joint statement by President Barack Obama and Indian Prime Minister Narenda Modi pledging to negotiate a harmonized approach to intellectual property protections and establish standard definitions for what is patentable. Read More
The Supreme Court wasted no time in acting on the precedent it set last week in its Copaxone ruling, sending several patent cases, including one Hatch-Waxman dispute, back to the appellate level. Read More
A new report finds growing support among pharma executives for the FDA to evaluate drug candidates on both their clinical and economic effectiveness, with 43 percent of drug company execs supporting the concept compared with 14 percent in 2010.
Read More